At the American Association for the Study of Liver Diseases (AASLD) annual meeting, a session highlighted new guidance on ...
The deal, one of two multibillion-dollar buyouts from Merck this year, centers around a drug that could become an alternative ...
Merck ( MRK) to acquire Cidara Therapeutics ( CDTX) for $221.50 per share in cash, for a total transaction value of ...
Merck will acquire Cidara Therapeutics in a nearly $9.2 billion deal, the companies said on Friday, gaining access to an experimental drug for flu prevention.
Insight Molecular Diagnostics Inc. is rated Hold due to upcoming catalysts & pending FDA submission for GraftAssureDx. Read ...
Merck & Co. has struck a $9.2 billion deal to buy biotechnology company Cidara Therapeutics in a move that bolsters the drugmaker's respiratory portfolio and pipeline as it braces for the 2028 loss of ...
Merck & Co. has struck a $9.2 billion deal to buy biotechnology company Cidara Therapeutics in a move that bolsters the drugmaker's respiratory portfolio and pipeline as it braces for the looming loss ...
Medtronic (NYSE: MDT) today announced new data supporting its Aurora and OmniaSecure defibrillation technology offerings.
Natera's integration into OncoEMR enhances workflow efficiency, simplifying the ordering process for precision medicine tests in oncology practices. The integration supports timely treatment decisions ...
Papillary muscle scarring (papSCAR) as detected by dark blood delayed-enhancement cardiovascular magnetic resonance (CMR) was ...
Pharmaceutical Technology on MSN
MSD bets big on flu antivirals with $9.2bn buyout of Cidara
MSD has now agreed two deals around the $10bn mark in 2025 as it looks to shore up its pipeline with Keytruda’s looming ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback